Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis

Journal of Cystic Fibrosis

Volumn 13, Issue 1, 2014, Pages 63-68

  Moffitt, K L ^a   Martin, S L ^a   Jones, A M ^b   Webb, A K ^b   Cardwell, C ^c   Tunney, M M ^a   Elborn, J S ^c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antibody titre; Cystic Fibrosis; Inflammation; Mortality; Proteases; Pseudomonas aeruginosa

Indexed keywords

BACTERIUM ANTIBODY; BIOLOGICAL MARKER; CATHEPSIN B; CATHEPSIN S; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM SURVIVAL; MALE; MORTALITY; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PSEUDOMONAS AERUGINOSA; SPECTROPHOTOMETRY; SPUTUM; SURVIVAL;

ANTIBODY TITRE; CYSTIC FIBROSIS; INFLAMMATION; MORTALITY; PROTEASES; PSEUDOMONAS AERUGINOSA;

ADULT; ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; CATHEPSIN B; CATHEPSINS; CYSTIC FIBROSIS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN-6; INTERLEUKIN-8; KAPLAN-MEIER ESTIMATE; LEUKOCYTE ELASTASE; MALE; MULTIVARIATE ANALYSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SPUTUM; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84890439292     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.06.002     Document Type: Article

References (35)

1. Hartl D., Gaggar A., Bruscia E., et al. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 2012, 11:363-382.
2. Mayer-Hamblett N., Aitken M.L., Accurso F.J., et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Crit Care Med 2007, 175:822-828.
3. Jones A.M., Martin L., Bright-Thomas R.J., et al. Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa. Eur Respir J 2003, 22:503-506.
4. Martin S.L., Moffitt K.L., McDowell A., et al. Association of airway cathepsin B and S with inflammation in cystic fibrosis. Pediatr Pulmonol 2010, 45(9):860-868.
5. Høiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl 1977, 262:1-96.
6. Pier G.B. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. J Infect Dis 1985, 151:575-580.
7. Høiby N., Koch C. Maintenance treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Thorax 2000, 55:349-350.
8. Høiby N. Antibodies against Pseudomonas aeruginosa in patients with bronchiectasis: helpful or harmful?. Thorax 2001, 56:667-668.
9. Høiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of P. aeruginosa and the humoral immune response. Acta Pathol Microbiol Scand B Microbiol Immunol 1974, 82(4):551-558.
10. Buret A., Cripps A.W. The immunoevasive activities of Pseudomonas aeruginosa: relevance for cystic fibrosis. Am Rev Respir Dis 1993, 148:793-805.
11. Brett M.M., Simmonds E.J., Ghoneim A.T.M., Littlewood J.M. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Arch Dis Child 1992, 67:1086-1088.
12. Burns J.L., Gibson R.L., McNamara S., et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001, 183:444-452.
13. Cordon S.M., Elborn J.S., Rayner R.J., Hiller E.J., Shale D.J. IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis. Arch Dis Child 1992, 67:737-740.
14. Tramper-Stranders G.A., van der Ent C.K., Wolfs T.F.W. Detection of Pseudomonas aeruginosa in patients with cystic fibrosis. J Cyst Fibros 2005, 4:37-43.
15. Weisner A.M., Chart H., Bush A., Davies J.C., Pitt T.L. Detection of antibodies to Pseudomonas aeruginosa in serum and oral fluid from patients with cystic fibrosis. J Med Microbiol 2007, 56:670-674.
16. Farrell P.M., Govan J.R. Pseudomonas serology: confusion, controversy and challenges. Thorax 2006, 61(8):645-647.
17. Pressler T., Frederiksen B., Skov M., Garred P., Koch C., Høiby N. Early rise of anti-pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection - a case control study. J Cyst Fibros 2006, 5:9-15.
18. Ratjen F., Walter H., Haug M., Meisner C., Grasemann H., Doring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007, 42(3):249-255.
19. Johansen H.K., Nørregaard L., Gøtzsche P.C., Pressler T., Koch C., Høiby N. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success? - a 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr Pulmonol 2004, 37:427-432.
20. Watt A., Ross O.A., Courtney J., Middleton D., Ennis M., Elborn J.S. Frequency of cytokine gene promoter polymorphisms in the Northern Ireland cystic fibrosis population. J Cyst Fibros 2007, 6:363-365.
21. Pressler T., Karpati F., Granstrom et al. Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J Cyst Fibros 2009, 8:37-42.
22. Taggart C.C., Greene C.M., Smith S.G., et al. Inactivation of human β-defensins 2 and 3 by elastinolytic cathepsins. J Immunol 2003, 171:931-937.
23. Bertiolini J.N., Benson E.M. The role of human interleukin-6 in B-cell isotype regulation and differentiation. Cell Immunol 1990, 125(1):197-209.
24. Kaltreider H.B. Expression of immune mechanisms in the lung. Am Rev Respir Dis 1976, 113:347-379.
25. Quie P.D. Lung defence against infection. J Paediatr 1986, 108:813-816.
26. Moss R.B. Immunology of cystic fibrosis: immunity, immunodeficiency and hypersensitivity. Textbook of Cystic Fibrosis 1983, 109-151. John Wright, Bristol. J.D. Lloyd-Still (Ed.).
27. Brett M.M., Ghoneim A.T.M., Littlewood J.M. An ELISA to detect antipseudomonal IgA antibodies in sera of patients with cystic fibrosis. J Clin Pathol 1988, 41:1130-1134.
28. Brett M.M., Ghoneim A.T.M., Littlewood J.M. Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis. Arch Dis Child 1990, 65:259-263.
29. Pedersen S.S., Espersen F., Høiby N. Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol 1987, 25:1830-1836.
30. Brett M.M., Ghoneim A.T.M., Littlewood J.M. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis. Arch Dis Child 1986, 61:1114-1120.
31. Schiotz P.O., Nielsen H., Høiby N., Glickmann G., Svehag S.E. Immune complexes in the sputum of patients with cystic fibrosis suffering from chronic Pseudomonas aeruginosa lung infection. Acta Pathol Microbiol Scand 1978, 86C:37-40.
32. McFarlane H., Holzel A., Brenchely P., Allan J.D., Wallwork J.C., Singer B.E., Worsley B. Immune complexes in cystic fibrosis. Br Med J 1975, 1:423-428.
33. Pressler T., Pedersen S.S., Espersen F., Høiby N. Koch c. IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic P. aeruginosa infection investigated by ELISA. Clin Exp Immunol 1990, 81:428-434.
34. Yamashita M., Hida Y., Sugimoto H., et al. A specific serum IgA antibody discriminates pneumonia from colonization state in patients with Pseudomonas aeruginosa in sputum culture. J Microbiol Methods 2010, 82:198-204.
35. Jones A.M., Dodd M., Morris J., Doherty C., Govan J.R.W., Webb A.K. Clinical outcome for cystic fibrosis patients infected with transmissible Pseudomonas aeruginosa: an 8-year prospective study. Chest 2010, 137(6):1405-1409.